Latest news and press releases about Drugs Made In America Acquisition II Corp. (DMIIR): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Drugs Made In America Acquisition II Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The company was founded on August 23, 2024 and is headquartered in Fort Lauderdale, FL.
Price
| Price | $0.07 |
| Market Cap | $5M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 0.40 |
| Price / Book | 0.01 |
| EV / EBITDA | -5.24 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 2.66% |
| Return on Invested Capital | -0.28% |
| Return on Assets | 2.53% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Explore sector: Financial Services · Financial - Conglomerates
More sections of DMIIR: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks